Molbrick is a start-up developing novel antimicrobial agents to treat drug-resistant mycobacteria.

It has designed small-molecule target cellular compartments that are essential for DNA replication.

Molbrick's platform technology was developed in Dr.

Barak Akabayov's lab at Ben-Gurion University.